A Digital Platform to Optimize Guideline-Directed Heart Failure Therapy: Rationale and Design of the AIM-POWER Trial.

Adam D Devore¹, Jiecheng Xie², Leigh Etters², Efren Rael², Sandi Wibowo², Chen Hao², Maulik Majmudar², Adrian F Hernandez³, Gregg C Fonarow⁴, Akshay S Desai⁵

¹Duke Clinical Research Institute and Department of Medicine, Duke University School of Medicine, Durham, NC. Electronic address: adam.devore@duke.edu.

²Biofourmis, Needham, MA.

³Duke Clinical Research Institute and Department of Medicine, Duke University School of Medicine, Durham, NC.

⁴Ronald Reagan-UCLA Medical Center, Los Angeles, CA.

⁵Cardiovascular Division, Brigham and Women's Hospital, Boston, MA.

PubMed DOI

Abstract

BACKGROUND: Patients with heart failure (HF) remain at high risk for hospitalization and death, in part, due to underuse of available HF pharmacological therapy. Digital interventions may facilitate rapid initiation and titration of HF pharmacological therapy, but they have not been systematically evaluated in adequately powered, randomized, control trials. In the AIM-POWER study, we evaluated the…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.